TNFSF11 and osteoporosis: Certain medications used for treating osteoporosis act by preventing bone loss, such as bisphosphonates, raloxifene, calcitonin, and denosumab, which is a monoclonal antibody inhibitor of RANKL that suppresses osteoclast development; however, these medications have limitations and adverse effects [17].